OpenSourceMalaria:Compound Series: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
Matthew Todd (talk | contribs) mNo edit summary |
Matthew Todd (talk | contribs) mNo edit summary |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{OpenSourceMalaria}} | {{OpenSourceMalaria}} | ||
[[OpenSourceMalaria: | A summary of progress in the OSM project may be found in the [[OpenSourceMalaria:Story_so_far|Story so Far]]. The pages below include the technical detail of the individual series examined and are written for scientific contributors. | ||
[[OpenSourceMalaria: | [[OpenSourceMalaria:GSK_Arylpyrrole_Series |'''Series 1: GSK Arylpyrroles''']] (being written up) | ||
[[OpenSourceMalaria:GSK_Amino-thienopyrimidine_Series |'''Series 3: GSK Thienopyrimidines''']] | [[OpenSourceMalaria:GSK_Triazolourea_Singleton |'''Series 2: GSK Triazoloureas''']] (parked) | ||
[[OpenSourceMalaria:GSK_Amino-thienopyrimidine_Series |'''Series 3: GSK Thienopyrimidines''']] (final compounds being made) | |||
[[OpenSourceMalaria:Triazolopyrazine_(TP)_Series |'''Series 4: Triazolopyrazines (TPs)''']] (currently most active) | |||
[[OpenSourceMalaria:Synthesis Branches |'''Synthetic Branches''']] | |||
[[OpenSourceMalaria:Obtaining Compounds for OSM |'''Obtaining Compounds for OSM''']] | |||
[[OpenSourceMalaria:Repurposing |'''Repurposing''']] | |||
[[OpenSourceMalaria:Other_GSK_Series_Under_Consideration |'''Other Possible GSK Series''']] | [[OpenSourceMalaria:Other_GSK_Series_Under_Consideration |'''Other Possible GSK Series''']] | ||
[[OpenSourceMalaria:Epigenetic Regulation of Life Cycle | '''Epigenetic Regulation of Lifecycle''']] | |||
Revision as of 06:38, 15 September 2015
A summary of progress in the OSM project may be found in the Story so Far. The pages below include the technical detail of the individual series examined and are written for scientific contributors.
Series 1: GSK Arylpyrroles (being written up)
Series 2: GSK Triazoloureas (parked)
Series 3: GSK Thienopyrimidines (final compounds being made)
Series 4: Triazolopyrazines (TPs) (currently most active)
